A new framework agreement for CALYM

AstraZeneca, the Carnot CALYM Institute and Inserm Transfert for Inserm sign a framework agreement for R&D collaboration in lymphomas

In order to accelerate the search for therapeutic solutions for lymphoma patients, the three partners have decided to pool their expertise by signing a tripartite agreement. This partnership sets up the conditions for the collaboration between the pharmaceutical group AstraZeneca, research teams from the Carnot CALYM Institute network and Inserm Transfert, Inserm’s private subsidiary, representing the research teams. This 3-year collaboration will allow the funding of up to two projects per year.

This agreement defines the terms of the collaboration with respect to governance, funding, intellectual property, exploitation of results and eligibility of research projects. It provides a platform facilitating the alliance between AstraZeneca’s R&D, bringing new drug candidates from its technology platforms of excellence, and the world-renowned expertise of the academic teams of the CALYM’s network, dedicated to the pathophysiology of lymphomas.


According to Bertrand Nadel, Director of CALYM, “Successful therapeutic innovation today requires interfacing academic expertise with R&D practices and the drug development value chain and intensifying the dialogue between public and private players. AstraZeneca’s commitment to connecting the Discovery/Innovation/Transfer segments makes it a partner of choice for our Carnot CALYM Institute to meet this challenge”.


To access English version enable subtitles in the Youtube video and choose English

In the three months following the agreement, two projects have already been launched: INOVO and INTREPIDS.

The INOVO project will use an original model of diffuse large B-cell lymphoma (DLBCL) PDX (xenotransplant derived from patient tumors) developed by OncoFactory to screen and characterize the response of a panel of experimental molecules at the molecular level. This unique model will allow the study of patients’ cells in a rapid and reproducible manner.

To view the video in English version enable subtitles in the Youtube video and choose English.

Moreover, the INTREPIDS project aims to evaluate the potential of immunotherapy in the central nervous system lymphomas. Based on patients’ samples, a screening of molecules modulating the immune response will be carried out on different models to identify the most promising strategies for future treatment of patients suffering from this rare pathology.

To view the video in English version enable subtitles in the Youtube video and choose English.